chrisvoncsefalvay/vaers-outcomes huggingface dataset:
head ache/ got a head ache that lasted 2 days and has gone down the neck; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (head ache/ got a head ache that lasted 2 days and has gone down the neck) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced HEADACHE (head ache/ got a head ache that lasted 2 days and has gone down the neck). The patient was treated with PARACETAMOL (TYLENOL) for Headache, at an unspecified dose and frequency. At the time of the report, HEADACHE (head ache/ got a head ache that lasted 2 days and has gone down the neck) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Redness, heat, swelling and tenderness of entire right arm from shoulder (injection site) to wrist starting Friday evening and ending on Monday morning.
This spontaneous report was received from a 76 year old female patient referring herself. The patients current condition included chronic lymphocytic leukemia (also reported as diagnosed years before). Concomitant medications included immunotherapy medication (unspecified). The patient's medical history and rug reactions/allergies was not reported. On an unknown date in 2011, the patient was vaccinated with 1st dose of PNEUMOVAX 23 injection (strength, dose, route of administration, lot # and expiry date were not reported) and 2nd dose injection possibly in 2016 or 2017 to avoid pneumococcal disease. It was reported that the patient was "in remission for CLL" (chronic lymphocytic leukaemia) (unspecified when remission occurred). The patient's physician recommended her to receive another revaccination with PNEUMOVAX 23 (circumstance or information capable of leading to medication error). It was reported that the No product quality complaint (PQC) was involved.
anxiety attack; heart racing; intense feeling of heat in body; tired; shortness of breath; This is a spontaneous report from a contactable other HCP (patient). A 55-year-old male patient received BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in arm left on 24Apr2021 16:30 (Batch/Lot number was not reported) as single dose for covid-19 immunisation.  Medical history included allergy. There were no concomitant medications and the patient did not receive any other medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19. The patient previously took levofloxacin and experienced allergy.  The patient reported that approximately three minutes after taking the vaccine 24Apr2021 16:33 (also reported as 17:15), still waiting for the recommended 15 minutes to be released, he started to feel his heart racing and a very intense feeling of heat in body. After reporting to the nurse at the location, she listened to his heart asking him to take a deep breath several times. According to the nurse, he had an anxiety attack, as she did not show any signs of anaphylaxis. However, he felt very tired and the night with a little shortness of breath. He would like to know if he go for the second dose or look for another vaccine. the patient did not receive treatment for the events and the outcome of the events was resolved in 2021.  Information on the lot/batch number has been requested.
Initial report received on 14/Nov/2005 from a health care professional. A female patient had received an administration (route and site not reported) of Fluzone SV (lot number not reported) on an unspecified date. At an unspecified time later the patient developed eye problems (not otherwise specified). No further information was provided. Follow up information received on 21/Apr/2006 from a health care provider. The reporter indicates that she was unable to reach the patient and that no further information is available.
Patient developed cellulitis after the administration of a Zostavax vaccine.  The site of administration was red, swollen, warm, and tender.  The affected area extended from the underside of the right tricep to the elbow.  The vaccine was given on 4/14/15.  Redness developed on 4/15/15. The patient went to the emergency room on 4/17/15.  Patient was diagnosed with cellulitis and treated with doxycycline hyclate 100 mg twice daily for one week.
This is a spontaneous report from a Pfizer-sponsored program from a contactable consumer. A 15-year-old male patient (reporters son) received first dose of TRUMENBA at single dose in Jul2017 for immunization. Medical history and concomitant medications were not reported. In Jul2017, patient received the first dose and he played tennis after receiving the vaccine. He was really sick and got a fever that lasted two days. He had sore muscles in the arm he was injected in (consumer thinks it was the left arm) and the sore muscles lasted three days. Outcome of event sickness was unknown, outcome of other events was recovered.
Nausea; Upset stomach; Arm sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 48 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 29Mar2021 (Lot number: ER2413) at the age of 48 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NAUSEA (non-serious) with onset 30Mar2021, outcome "not recovered", described as "Nausea"; ABDOMINAL DISCOMFORT (non-serious) with onset 30Mar2021, outcome "not recovered", described as "Upset stomach"; PAIN IN EXTREMITY (non-serious) with onset 29Mar2021, outcome "recovering", described as "Arm sore".  Additional information: Patient got the first shot of Pfizer Covid vaccine on Monday morning, 29Mar2021, caller stated she has had some side effects of nausea and her stomach is so upset, this was her fourth day dealing with this and she still has it. Satated it comes in waves, cannot stop the on and off of it, has never had this problem before.  No follow-up attempts are possible. No further information is expected.
Headache, Myalgia, Arthralgia, fatigue, injection site pain Narrative:
Fever infection site tenderness, arm pain, sore, chills, fatigue, brain fog Narrative:
Severe headache one hour post vaccine. Complaining of pain in forehead and stinging sensation. Piercing scream have never heard her cry like this in pain.
I developed a red hard swollen arm after receiving a booster dose; I developed a red hard swollen arm after receiving a booster dose; I developed a red hard swollen arm after receiving a booster dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (I developed a red hard swollen arm after receiving a booster dose), VACCINATION SITE SWELLING (I developed a red hard swollen arm after receiving a booster dose) and VACCINATION SITE INDURATION (I developed a red hard swollen arm after receiving a booster dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (I developed a red hard swollen arm after receiving a booster dose), VACCINATION SITE SWELLING (I developed a red hard swollen arm after receiving a booster dose) and VACCINATION SITE INDURATION (I developed a red hard swollen arm after receiving a booster dose). At the time of the report, VACCINATION SITE ERYTHEMA (I developed a red hard swollen arm after receiving a booster dose), VACCINATION SITE SWELLING (I developed a red hard swollen arm after receiving a booster dose) and VACCINATION SITE INDURATION (I developed a red hard swollen arm after receiving a booster dose) outcome was unknown.            The patient wants to know how to treat the reactions.   Treatment  information was unknown
has little red dots. Which spread in her back and all over her body but more under her arm/She is itching, she has a rash; She is itching, she has a rash; Headaches; She received the vaccine in her left thigh. She been complaining her leg hurt; This spontaneous case was reported by a patient family member or friend and describes the occurrence of RASH MACULAR (has little red dots. Which spread in her back and all over her body but more under her arm/She is itching, she has a rash), RASH PRURITIC (She is itching, she has a rash), HEADACHE (Headaches) and VACCINATION SITE PAIN (She received the vaccine in her left thigh. She been complaining her leg hurt) in a 3-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1416B) for COVID-19 vaccination.     The patient never tested positive or diagnosed with COVID-19. The patient did not have any allergies related to medications, food and other products.     On 26-Aug-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH MACULAR (has little red dots. Which spread in her back and all over her body but more under her arm/She is itching, she has a rash), RASH PRURITIC (She is itching, she has a rash), HEADACHE (Headaches) and VACCINATION SITE PAIN (She received the vaccine in her left thigh. She been complaining her leg hurt). At the time of the report, RASH MACULAR (has little red dots. Which spread in her back and all over her body but more under her arm/She is itching, she has a rash), RASH PRURITIC (She is itching, she has a rash), HEADACHE (Headaches) and VACCINATION SITE PAIN (She received the vaccine in her left thigh. She been complaining her leg hurt) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.
Information has been received from a female patient who on an unspecified date was vaccinated with a dose of MMR II (Lot #, expire date and route not reported). Patient stated that on an unspecified date when she was 12 month old, she experienced a reaction to MMR II. At the time of the report, patient's outcome was unknown. Additional information has been requested.
Patient came in for MENVEO shot, five days later came back with numbness in the area.
This spontaneous report as received from a nurse refers to unknown number of patients of unknown demographics. No information about medical history, concurrent conditions and concomitant medications were reported. The reporter stated that unknown number of patients were vaccinated with RECOMBIVAX HB (dose, strength, route not reported) that had been improperly stored. Approximately on an unknown date in July 2014 (reported as between 09-JUL-2014 and 16-JUL-2014). No adverse effects reported. The outcome of events reported is unknown. No product quality complaint was involved. This is one of the several reports received from the same source. Additional information has been requested.
This case was reported by a consumer via call center representative and described the occurrence of adverse reaction in a adult female patient who received RABAVERT. On an unknown date, the patient received RABAVERT at an unknown dose. On an unknown date, an unknown time after receiving RABAVERT, the patient experienced adverse reaction and nervous. On an unknown date, the outcome of the adverse reaction and nervous were unknown. It was unknown if the reporter considered the adverse reaction and nervous to be related to RABAVERT. Additional details were provided as follows: After vaccination with RABAVERT, the patient experienced strange reactions (adverse reaction) and the vaccines was making her very nervous. The patient refused to provide any clarification regarding the reported events. No additional information was obtained including lot number and expiration date as the patient refused to provide information for the report.
Before the injection I mentioned a post nasal drip. Took my temp, but normal. Later in the afternoon I was feeling chilly. Towards evening, possibly 5 pm, I called the doctors office and mentioned not feeling myself (very chilly, but no fever). They asked if I wanted to be seen in the office, but did not. Later around 6 pm I became extremely cold (still no temperature). Within the hour I began shaking as if I had a high temperature or going into shock. At that point I went to bed. By morning I was much better, but extremely tired.
Pt states that she felt drunk and confused yesterday after the shot. Now having pain, redness and swelling at injection site. No systemic symptoms currently.
MMR's Varivax R deltoid 12 x 16cm non tender erythema and swelling. DTap; Influenza L deltoid 10 x 7cm non tender and swelling 3 day post immunization. Parents state that swelling started a few hours after injections.
Red swollen arm. Hives and itching rash over her body. Went to doctor and her prescribed her prednisone. Also she went to the dermatologist and they prescribed her antihistamine
Hearing  soft sound of rushing water thru water pipe L ear following bilat ear wash x2 Dec '20. Heard only at night when quite as soon as I laid down. Awoke ea AM w/ mild HA disappearing when I got up. But as of 04/02 (2 days post #1 Moderna vaccine), sound now 24 hrs a day and louder in L ear. (04/17, I just sent email to my MD to report it).
T103.5 evening of 1st DTAP;marked irritability & also change & dec in nl activity;full recovery by 48hr;
This case was reported by a consumer via sales rep and described the occurrence of lower extremities weakness of in a 93-year-old male patient who received SHINGRIX. Concurrent medical conditions included congestive heart failure (with multiple comorbidities) and fatigue. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced lower extremities weakness of (serious criteria disability). The patient was treated with Steroid Pack (NOS). On an unknown date, the outcome of the lower extremities weakness of was recovered/resolved. It was unknown if the reporter considered the lower extremities weakness of to be related to SHINGRIX. Additional details were provided as follows: This case was received from Office Manager and Nurse Practitioner. The patient was on multiple comorbidities and on many medications (unknown). On Thursday, the patient received dose of SHINGRIX vaccine at a local pharmacy. The patient was seen the next day in the physician office for weakness in his legs that required wheelchair use. The exact dates of the vaccination and events were unknown but the patient stated that he was vaccinated on a Thursday and saw the Nurse Practitioner the next day on Friday initially in the office and given the steroid pack. The patient was seen back on Tuesday and was back to his normal. The Nurse Practitioner stated he was not convinced the weakness was from the vaccination. The patient however was convinced it was the vaccine.
C/O frontal HA approx. 30 minutes after  H1N1 nasal spray vaccine.
large rash on right upper arm around injection site that has now covered most of upper arm starting on 2/7/21; although tired day after, extreme fatigue starting on 2/8/21 and sleeping almost all day, every day including today 2/12/21; all over body pain, especially in upper body and arms; None have resolved as of today 2/12/21, 7 days after 2nd dose date
Pt received Tdap, Flu and HPV shots. Immediately after 3rd shot (HPV) pt c/o not feeling well, then had approx 10 seconds of tonic-clonic seizure activity, and became unresponsive. She woke up about 30 sec. later, confused and mildly combative. She was diaphoretic, c/o bad headache. B/P 160/94 P 88 O2 sat 84%. O2 applied, drank water, v/s improved: 129/84 P 66 O2 sat 99%. Pt c/o hands tingling, pounding H/A weepy and confused. Sent to ER.
Period is all out of whack, started early after first dose and now spotting after second two weeks early.
This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 70-year-old female patient who received SHINGRIX (batch number L9CS4, expiry date 22nd February 2021) for prophylaxis. On 25th August 2018, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced pain in arm and weakness of arms. On an unknown date, the outcome of the pain in arm was not recovered/not resolved and the outcome of the weakness of arms was unknown. It was unknown if the reporter considered the pain in arm and weakness of arms to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the left arm. The pain had not resolved and her arm was weaker than normal and when rolling over onto in the night it woke her up due to the pain. This case has been linked with case US2018172577, reported by same reporter.
Normal labor and delivery on 2/27/2022. Hospital admission within 6 weeks of receiving the COVID vaccine.
Muscle soreness all over body after first shot / Achy all over the body after first shot; Tired after first shot; Cold sweats after first shot; Hot sweat after first shot; This spontaneous case was reported by a consumer and describes the occurrence of COLD SWEAT (Cold sweats after first shot), HYPERHIDROSIS (Hot sweat after first shot), MYALGIA (Muscle soreness all over body after first shot / Achy all over the body after first shot) and FATIGUE (Tired after first shot) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, the patient experienced COLD SWEAT (Cold sweats after first shot) and HYPERHIDROSIS (Hot sweat after first shot). On 24-Apr-2021, the patient experienced MYALGIA (Muscle soreness all over body after first shot / Achy all over the body after first shot) and FATIGUE (Tired after first shot). On 01-Oct-2021, COLD SWEAT (Cold sweats after first shot) and HYPERHIDROSIS (Hot sweat after first shot) had resolved. At the time of the report, MYALGIA (Muscle soreness all over body after first shot / Achy all over the body after first shot) and FATIGUE (Tired after first shot) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided by the reporter. It was reported that the patient took steroids shot as a treatment which helped tremendously to the patient.  Patient took second dose of Moderna COVID-19 vaccine on 23MAY2021 and batch no is 033B21A.
June 1 Sun- fever, chills, abdominal pain, diarrhea lasting 3 days. Symptoms subsided-she then felt well. No reaction at site of injection. She was in contact, prior to 5-29 with person who had similar symptoms.
ERYTHEMA, INDURATION OF 4 X 3.5 INCHES, TREATED WITH TYLENOL
Has not been able to get the second dose yet; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Has not been able to get the second dose yet) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Has not been able to get the second dose yet). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Has not been able to get the second dose yet) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.  This report refers to a case of Product dose omission issue for mRNA-1273, lot # unknown with no associated AEs.; Sender's Comments: This report refers to a case of Product dose omission issue for mRNA-1273, lot # unknown with no associated AEs.
This spontaneous report was received from a registered nurse and refers to a 13 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 11-AUG-2017, the patient was vaccinated with an improperly stored VARIVAX at a dose of 0.5 (units not specified) from lot # N000683 with expiry date: 06-JAN-2019 (dose number, route, anatomical location and site of administration were not reported) for prophylaxis. Concomitant medications included a properly stored sterile diluent (manufacturer unknown). The administered dose of vaccine was stored in the temperature between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 20 hours and in the temperature between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 6 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No additional information was provided. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1707USA004945.
This spontaneous report as received from a healthcare worker refers to 2 unspecified male patients, over the age of 15 years. On an unknown date the patients were vaccinated (on parents request) with doses of GARDASIL 9 (dose, frequency, route of administration and indication were not reported, lot number and expiration dates unspecified). No adverse experience was reported. Additional information has been requested.
A non-serious report of expired dose of vaccine administered was received from a physician concerning a five-year-old female. No medical history or concomitant medications were reported. The patient received FluMist vaccine on 05-Feb-2008. The FluMist vaccine administered had an expiration date of 31-Dec-2007. Follow-up call to the reporter after four weeks on 04-Mar-2008 confirmed that the patient did not experience any adverse events after receiving expired FluMist vaccine. The patient did not experienced a rechallenge while receiving the suspect product. The reporter did not provide a statement of causality. The reporting source of this case is spontaneous, thus the sponsor's comment is not applicable. Additional information received on 04-Mar-2008 : reporter confirmed did not experience adverse events.
Pt recvd MMR/HIB vax & devel an urticarial rash; tx DPH @ time of report sx resolving;
pain in rt shoulders, arm & back pain;very weak;c/o pain in rt arm & muscle aches;pain in arm where recv vax;feverish;body aches;BP 130/80;T100.4;HR 84, R 14;rt arm pain & gen body aches secondary to influenza vax rxn;